Relation of Multiple Inflammatory Biomarkers to Incident Atrial Fibrillation

Overview

Journal Am J Cardiol

Specialty Cardiology & Vascular Diseases

Date 2009 Jul 7

PMID 19576326

Citations 64

Authors

Renate B Schnabel

Martin G Larson

Jennifer F Yamamoto

Sekar Kathiresan

Jian Rong

Daniel Levy

John F Keaney Jr

Thomas J Wang

Ramachandran S Vasan

Emelia J Benjamin

Affiliations

Soon will be listed here.

Abstract

Basic and clinical studies have suggested that inflammation predisposes to atrial fibrillation (AF). We assessed the association of 12 circulating inflammatory biomarkers (i.e., C-reactive protein, fibrinogen, interleukin-6, intercellular adhesion molecule-1, lipoprotein-associated phospholipase A2 [mass and activity], monocyte chemoattractant protein-1, myeloperoxidase, CD40 ligand, osteoprotegerin, P-selectin, and tumor necrosis factor receptor II) with incident AF in 2863 Framingham Offspring Study participants (mean age 60.7 years, SD = 9.4, 55% women). During follow-up (median 6 years), 148 participants (43% women) developed incident AF. In the multivariable proportional hazards models, the inflammatory biomarker panel was associated with incident AF (p = 0.03). With stepwise selection (p <0.01 for entry and retention), log-transformed osteoprotegerin was associated with incident AF (hazard ratio per SD 1.30, 95% confidence interval 1.08 to 1.56, p = 0.006). Adjusting for interim myocardial infarction or heart failure attenuated the association between osteoprotegerin and incident AF (hazard ratio 1.18, 95% confidence interval 0.98 to 1.43, p = 0.09). In conclusion, circulating osteoprotegerin concentration was significantly associated with incident AF in our community-based sample, possibly mediated by interim cardiovascular events.

Citing Articles

Vascular Cell Adhesion Molecule 1 in atrial fibrillation.

Jiang Z, Lin Y, Ding H, Lian L, Chen J, Wu M BMC Cardiovasc Disord. 2024; 24(1):725.

PMID: 39707193 PMC: 11661320. DOI: 10.1186/s12872-024-04404-x.

The effect of icosapent ethyl on left atrial and left ventricular morphology.

Kitchin S, Lakshmanan S, Kinninger A, Mao S, Rabbat M, Bhatt D Br J Cardiol. 2024; 30(3):22.

PMID: 39144091 PMC: 11321466. DOI: 10.5837/bjc.2023.022.

Forecasting Atrial Fibrillation: The Predictive Power of N-terminal Prohormone of Brain Natriuretic Peptide in a Five-Year Study.

Akbar F, Lal D, Arshad M, Imran M, Zaman M, Usmani S Cureus. 2024; 16(6):e62515.

PMID: 39022500 PMC: 11253072. DOI: 10.7759/cureus.62515.

Predictors of left atrial appendage thrombus in atrial fibrillation patients undergoing cardioversion.

Ruzieh M, Bai C, Meisel E, Kramer E, Frechette R, Nassereddin A J Interv Card Electrophysiol. 2024; 67(9):2059-2066.

PMID: 38995603 DOI: 10.1007/s10840-024-01868-x.

Future Perspectives to Improve CHADSVASc Score: The Role of Left Atrium Remodelling, Inflammation and Genetics in Anticoagulation of Atrial Fibrillation.

Rachieru C, Luca C, Vacarescu C, Petrescu L, Cirin L, Cozma D Clin Interv Aging. 2023; 18:1737-1748.

PMID: 37873054 PMC: 10590594. DOI: 10.2147/CIA.S427748.

References

Conway D, Buggins P, Hughes E, Lip G . Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. Am Heart J. 2004; 148(3):462-6. DOI: 10.1016/j.ahj.2004.01.026. View

Fauchier L, Pierre B, De Labriolle A, Grimard C, Zannad N, Babuty D . Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2008; 51(8):828-35. DOI: 10.1016/j.jacc.2007.09.063. View

Chung M, Martin D, Sprecher D, Wazni O, Kanderian A, Carnes C . C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation. 2001; 104(24):2886-91. DOI: 10.1161/hc4901.101760. View

Omland T, Drazner M, Ueland T, Abedin M, Murphy S, Aukrust P . Plasma osteoprotegerin levels in the general population: relation to indices of left ventricular structure and function. Hypertension. 2007; 49(6):1392-8. DOI: 10.1161/HYPERTENSIONAHA.107.087742. View

Aviles R, Martin D, Apperson-Hansen C, Houghtaling P, Rautaharju P, Kronmal R . Inflammation as a risk factor for atrial fibrillation. Circulation. 2003; 108(24):3006-10. DOI: 10.1161/01.CIR.0000103131.70301.4F. View

Mukamal K, Tolstrup J, Friberg J, Gronbaek M, Jensen G . Fibrinogen and albumin levels and risk of atrial fibrillation in men and women (the Copenhagen City Heart Study). Am J Cardiol. 2006; 98(1):75-81. DOI: 10.1016/j.amjcard.2006.01.067. View

Schnabel R, Larson M, Dupuis J, Lunetta K, Lipinska I, Meigs J . Relations of inflammatory biomarkers and common genetic variants with arterial stiffness and wave reflection. Hypertension. 2008; 51(6):1651-7. PMC: 2892983. DOI: 10.1161/HYPERTENSIONAHA.107.105668. View

Bucay N, Sarosi I, Dunstan C, Morony S, Tarpley J, Capparelli C . osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998; 12(9):1260-8. PMC: 316769. DOI: 10.1101/gad.12.9.1260. View

Nellemann B, Gormsen L, Dollerup J, Schmitz O, Mogensen C, Rasmussen L . Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria. Diabetes Care. 2007; 30(12):3122-4. DOI: 10.2337/dc07-0919. View

10.

Pencina M, DAgostino R . Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med. 2004; 23(13):2109-23. DOI: 10.1002/sim.1802. View

11.

Roldan V, Marin F, Blann A, Garcia A, Marco P, Sogorb F . Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation. Eur Heart J. 2003; 24(14):1373-80. DOI: 10.1016/s0195-668x(03)00239-2. View

12.

Avignon A, Sultan A, Piot C, Mariano-Goulart D, Thuan Dit Dieudonne J, Cristol J . Osteoprotegerin: a novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients. Diabetes Care. 2007; 30(11):2934-9. DOI: 10.2337/dc07-0992. View

13.

Nakamura Y, Nakamura K, Fukushima-Kusano K, Ohta K, Matsubara H, Hamuro T . Tissue factor expression in atrial endothelia associated with nonvalvular atrial fibrillation: possible involvement in intracardiac thrombogenesis. Thromb Res. 2003; 111(3):137-42. DOI: 10.1016/s0049-3848(03)00405-5. View

14.

Kim S, Lee J, Ryu O, Lee K, Kim H, Seo J . Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity. Clin Endocrinol (Oxf). 2005; 63(5):594-8. DOI: 10.1111/j.1365-2265.2005.02390.x. View

15.

Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo M, Maseri A . Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation. 1997; 96(4):1180-4. DOI: 10.1161/01.cir.96.4.1180. View

16.

Healey J, Baranchuk A, Crystal E, Morillo C, Garfinkle M, Yusuf S . Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol. 2005; 45(11):1832-9. DOI: 10.1016/j.jacc.2004.11.070. View

17.

Neuman R, Bloom H, Shukrullah I, Darrow L, Kleinbaum D, Jones D . Oxidative stress markers are associated with persistent atrial fibrillation. Clin Chem. 2007; 53(9):1652-7. PMC: 3158654. DOI: 10.1373/clinchem.2006.083923. View

18.

Marcus G, Whooley M, Glidden D, Pawlikowska L, Zaroff J, Olgin J . Interleukin-6 and atrial fibrillation in patients with coronary artery disease: data from the Heart and Soul Study. Am Heart J. 2008; 155(2):303-9. PMC: 2247366. DOI: 10.1016/j.ahj.2007.09.006. View

19.

Crisafulli A, Micari A, Altavilla D, Saporito F, Sardella A, Passaniti M . Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. Clin Sci (Lond). 2005; 109(4):389-95. DOI: 10.1042/CS20050058. View

20.

Liu T, Li G, Li L, Korantzopoulos P . Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. J Am Coll Cardiol. 2007; 49(15):1642-1648. DOI: 10.1016/j.jacc.2006.12.042. View